



for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

study drugs were administered by medical personnel as dictated by local investigative site guidelines.

“ Fospropofol disodium injection was designed to help meet the need for new minimal to moderate sedation agents, and therefore is representative of our human health care mission to address the unmet medical needs of patients,” said Hajime Shimizu, Chairman and CEO, Eisai Corporation of North America.

[Please refer to the following note for Fospropofol Disodium Injection]

About Fospropofol Disodium Injection

Fospropofol disodium injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by an enzyme (alkaline phosphatase) in the body into propofol. Fospropofol disodium injection is a product candidate in development for sedation of patients undergoing therapeutic or diagnostic procedures. Fospropofol disodium injection has not yet been approved for marketing by the Food and Drug Administration or any other regulatory agencies.